Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zonisamide to prevent olanzapine-associated weight gain
NCT00363376Phase 3Completed
- Sponsor
- Lindner Center of HOPE
- Start
- Jan 2008
- Primary completion
- Feb 2011
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zonisamide, sponsored by Lindner Center of HOPE. Primary endpoint: Change in weight at 16 weeks. Started Jan 2008; status: completed.
02
Drugs
zonisamide
Beyond the preview
Go deeper on NCT00363376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363376.